{"nctId":"NCT01577238","briefTitle":"A Phase 3 Study of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis","startDateStruct":{"date":"2012-03-28","type":"ACTUAL"},"conditions":["Bacterial Vaginosis"],"count":250,"armGroups":[{"label":"VivaGel","type":"EXPERIMENTAL","interventionNames":["Drug: 1% SPL7013 Gel"]},{"label":"HEC Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"1% SPL7013 Gel","otherNames":["VivaGel"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key eligibility criteria:\n\n* Post-menarchal females, aged 12 years or more\n* Diagnosis of BV by Amsel criteria (ie all four of the following signs/symptoms: presence of white to grey homogeneous discharge; positive whiff test indicating an amine (fishy) odor with addition of potassium hydroxide; vaginal pH greater than 4.5; and presence at least 20% clue cells of total epithelial cells\n* Nugent score of at least 4\n* Otherwise healthy, as determined by medical history, physical examination\n* normal Pap smear at or documented within 24 months of screening","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Women With Clinical Cure at the End of Treatment Visit (EOT)","description":"Clinical Cure is defined as the resolution of clinical findings (ie Amsel criteria) from the Baseline visit (Day 1)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Women With Nugent Cure at the EOT Visit","description":"Nugent Cure is defined as a Nugent score of 0-3 (normal)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Women With Clinical Cure at the Test of Cure Visit (TOC)","description":"Clinical Cure is defined as the resolution of clinical findings (ie Amsel criteria) from the Baseline visit (Day 1)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Women With Nugent Cure at the TOC Visit","description":"Nugent Cure is defined as a Nugent score of 0-3 (normal)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Adverse Events Potentially Related to Treatment","description":"Number of participants with adverse events considered potentially related to study treatment","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":126},"commonTop":[]}}}